Please try another search
For the fiscal year ended 31 December 2020,Protagenic Therapeutics Inc revenues was not reported. Netloss increased 46% to $2.5M. Higher net loss reflectsStock-based Compensation in SGA increase of 94% to $1.4M(expense), Interest expense increase from $16K to $246K(expense), Change in fair value of derivative liabidecrease of 28% to $249K (income).
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -0.54 | -1.09 | -0.92 | -0.52 |
Net Income | -0.52 | -1.05 | -0.98 | -0.5 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Assets | 0.88 | 1 | 1.19 | 0.79 |
Total Liabilities | 2.03 | 2.02 | 1.93 | 1.37 |
Total Equity | -1.15 | -1.02 | -0.75 | -0.59 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -1.35 | -1.03 | -0.51 | -0.36 |
Cash From Investing Activities | 0 | 0 | 0 | |
Cash From Financing Activities | 1.22 | 1.22 | 0.9 | 0.33 |
Net Change in Cash | -0.13 | 0.19 | 0.38 | -0.04 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review